“…Several studies and reviews (Bartalena et al, 1995;Bartalena et al, 1998 b;Bartalena et al, 2002;Burch and Wartofsky, 1993;Heufelder, 2000;Miehle and Paschke, 2003;Prummel and Wiersinga, 1993;Tallstedt et al, 1994;Tellez et al, 1992;Wiersinga, 1999;Winsa et al, 1993) have suggested that in addition to the therapy modality, other confounding factors known to be associated with a higher risk of worsening or new development of GO may influence the posttherapeutical course of GO itself. These are smoking, relapse of hyperthyroidism, elevated TSH levels and high serum TSH-receptor antibody levels.…”